chufangao/CTO huggingface dataset:
Clinical trial NCT04539730: Liposomal Bupivacaine in Adductor Canal Blocks (ACB)
Official title: Does the Addition of Liposomal Bupivacaine to the Adductor Canal Block Impact Narcotic Use After Primary Total Knee Arthroplasty: a Prospective, Blind Randomized Control Trial
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Did not acquire funding to pursue study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2022-12-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT04357795: Effect of Cequa™ in Subjects With Dry Eye Disease
Official title: Effect of Cequa™ in Subjects With Dry Eye Disease That Is Currently Inadequately Controlled While on Cyclosporine 0.05% Ophthalmic Emulsion
Sponsor: Sun Pharmaceutical Industries Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 135.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-29
Primary completion date: 2022-06-24
Completion date: 2022-06-24
Clinical trial NCT03382574: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Official title: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-14
Primary completion date: 2021-10-22
Completion date: 2021-10-22
Baseline population: 2 participants consented at Tel Aviv Sourasky Medical Center, no participants randomized nor received trial intervention combined arms due to the participants were not randomized.
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Clinical trial NCT03037645: Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Official title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
Sponsor: Sunesis Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the Phase 1b to advance to Phase 2.
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-28
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT04760665: Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
Official title: Randomized, Superiority, Double Blind Controlled With Placebo, Clinical Trial, to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Klebsiella Pneumoniae Carbapenemase (KPC)-Producing
Acronym: KAPEDIS
Sponsor: Maimónides Biomedical Research Institute of Córdoba (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of elegible population
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-04
Primary completion date: 2023-11-24
Completion date: 2023-11-24
Plan to share individual participant data: YES
IPD time frame: After publishing the results in a journal.
IPD access criteria: Upon request to uicec@imibic.org
Clinical trial NCT03257267: Study of Cemiplimab in Adults With Cervical Cancer
Official title: An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 608.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-05
Primary completion date: 2021-03-15
Completion date: 2023-04-20
Baseline population: The FAS included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy
IPD access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Clinical trial NCT04839315: COVID-19 Vaccination in Rheumatic Disease Patients
Official title: Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Difficulty with enrollment
Enrollment: 58.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-15
Primary completion date: 2022-02-09
Completion date: 2022-02-09
Clinical trial NCT00493870: TAC Versus TC for Adjuvant Breast Cancer
Official title: Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Sponsor: US Oncology Research (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1961.0 (ACTUAL)
Number of arms: 2.0
Start date: 2007-05-29
Primary completion date: 2015-05-31
Completion date: 2020-03-30
Clinical trial NCT05086445: A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Official title: A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 62.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-11-12
Primary completion date: 2022-09-05
Completion date: 2022-09-05
Plan to share individual participant data: NO
Clinical trial NCT02834975: Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Official title: Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Investigator left institution
Enrollment: 26.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-22
Primary completion date: 2022-09-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 4 Study of the Efficacy & Safety of Patiromer for Oral Suspension in Combination With Standard of Care Treatment in ED Patients With Hyperkalemia
Acronym: PLATINUM
Sponsor: Comprehensive Research Associates (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment window ended
Enrollment: 115.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-08
Primary completion date: 2023-03-09
Completion date: 2023-06-03
Plan to share individual participant data: NO
Clinical trial NCT02319044: Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Official title: A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 267.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-04-15
Primary completion date: 2016-09-26
Completion date: 2020-07-06
Baseline population: Full analysis set - all randomized patients
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT05075538: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Official title: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Acronym: I-SPARC
Sponsor: Jules Bordet Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.
Enrollment: 152.0 (ACTUAL)
Start date: 2021-12-01
Primary completion date: 2024-01-08
Completion date: 2024-01-08
Clinical trial NCT05332483: Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
Official title: The Effect of Megestrol Acetate on Grade 2 Endometrioid Endometrial Cancer in Patients Waiting for Definitive Surgery, a Prospective Trial
Acronym: MA-EEC
Sponsor: Sunnybrook Health Sciences Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-05
Primary completion date: 2023-10-12
Completion date: 2023-10-12
Clinical trial NCT04438174: Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds
Official title: A Phase I/II Clinical Trial To Determine Safety And Feasibility Of Using An Acellular Amniotic Fluid Application To Expedite Healing In Chronic Wounds
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-31
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Baseline population: Enrollment was halted prematurely after enrolling one subject.
Limitations and caveats: Enrollment was halted prematurely after successful enrollment of one participant due to limited eligible participants. A single participant was enrolled in the treatment arm, hence we are unable to measure the safety and effectiveness of the intervention compared to standard care. We noted variation in wound size assessment for our single participant.
Plan to share individual participant data: NO
Clinical trial NCT03980249: Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
Official title: A Pilot Study: Evaluating the Anti-Cancer Effects of Carvedilol With TTFields and Standard of Care in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-30
Primary completion date: 2021-12-31
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT04562090: A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
Official title: A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 249.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-06
Primary completion date: 2022-03-17
Completion date: 2022-03-30
Baseline population: All Randomized Set consisted of all participants who were randomized and had a randomization number.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT04264533: Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
Official title: Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial
Sponsor: Zhongnan Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the study was started in the second half of the outbreak, and the number of qualifying COVID-19 patients decreased with the control of the epidemic so that we had to stop our trial before reaching the predefined sample size.
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-14
Primary completion date: 2020-03-02
Completion date: 2020-03-29
Plan to share individual participant data: NO
Clinical trial NCT04041284: A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 353.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-13
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Baseline population: The intent-to-treat (ITT) analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Clinical trial NCT03524261: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer
Official title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Breast Cancer
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-20
Primary completion date: 2020-04-05
Completion date: 2020-07-05
Clinical trial NCT03524339: Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
Official title: Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-01
Primary completion date: 2020-06-09
Completion date: 2020-06-09
Plan to share individual participant data: NO
Clinical trial NCT03403205: Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
Official title: A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to terminate the program
Enrollment: 214.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-22
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Baseline population: The Full Analysis Set included all randomized participants who received at least 1 dose of randomized treatment.~The Extension Analysis Set included all participants who entered the Extension Period and received at least 1 dose of ALXN1840 in the Extension Period. This included the participants who rolled over from Study WTX101-201.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04526821: Lactoferrin for Prevention of COVID-19 in Health Care Workers
Official title: Bovine Lactoferrin for the Prevention of COVID-19 Infection in Physicians and Nurses in Hospitals in Lima, Peru: a Double Blinded Randomized Clinical Trial (LF-COVID)
Acronym: LF-COVID
Sponsor: Universidad Peruana Cayetano Heredia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was interrupted due to the arrival and distribution of the vaccine to hospital workers in Peru
Enrollment: 209.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-17
Primary completion date: 2021-02-10
Completion date: 2021-02-10
Plan to share individual participant data: YES
IPD sharing description: Individual participant data collected during the trial, after deidentification, will be shared with researchers who provide a methodological sound study protocol previously approved by an independent ethics committee.
IPD time frame: Immediately following publication of the study,
IPD access criteria: Contact the study PI ( Theresa.ochoa@upch.pe)
Clinical trial NCT03742037: Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Official title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 427.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-12-21
Primary completion date: 2021-08-31
Completion date: 2022-08-25
Plan to share individual participant data: NO
Clinical trial NCT04171388: Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia
Official title: Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Amhara Region, Ethiopia
Acronym: ENAT
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Trial withdrawn due to COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-03-01
Primary completion date: 2021-05-28
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT03281044: Fecal Microbiota Transplantation in Depression
Official title: Oral Frozen Fecal Microbiota Transplantation (FMT) Capsules for Depression: a Double-blind, Placebo-controlled, Randomized Parallel Group Study
Sponsor: Psychiatric Hospital of the University of Basel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Although not observed in our patients (4 enrolled), SAEs have been reported in other patients receiving the same product.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-24
Primary completion date: 2020-03-16
Completion date: 2020-03-16
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03678480: A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
Official title: A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)
Sponsor: HighTide Biopharma Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Corporate decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-01
Primary completion date: 2021-10-04
Completion date: 2021-11-04
Plan to share individual participant data: NO